BiomX, Inc.(NYSE Amex Equities : PHGE)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||1.32%||697.33||2.6%||$644.85m|
|GILD||Gilead Sciences, Inc.||-1.43%||62.86||1.0%||$494.49m|
|VRTX||Vertex Pharmaceuticals, Inc.||-1.01%||283.45||1.9%||$355.83m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-5.81%||4.05||0.7%||$283.11m|
|SAVA||Cassava Sciences, Inc.||-18.00%||41.87||0.0%||$173.71m|
|NRBO||NeuroBo Pharmaceuticals, Inc.||-6.44%||15.54||0.0%||$89.03m|
|BMRN||BioMarin Pharmaceutical, Inc.||-0.09%||84.84||4.2%||$76.07m|
|EXAS||EXACT Sciences Corp.||-2.74%||33.41||17.6%||$71.49m|
|CRSP||CRISPR Therapeutics AG||-2.68%||63.16||0.6%||$69.53m|
BiomX, Inc. operates as a clinical-stage microbiome company. It engages in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis, and colorectal cancer. The firm discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.